Turku, Finland, 28 August 2014:
Montisera Ltd (“Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary novel 6,7-disubstituted-isoquinoline derivatives platform, announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 13/814,987, a patent which covers the use of novel 6,7-disubstituted-isoquinoline derivatives as a medicament, and particularly in the treatment of alcoholism, drug addiction and CNS related diseases. Montisera announces that also the European Patent Office (EPO) intends to grant a patent for the novel 6,7-disubstituted-isoquinoline derivatives, and the medical use thereof. The issued patents, based on applications drafted and prosecuted by Kolster Oy Ab, the leading intellectual property service agency in Finland, will provide an exclusivity period until August 2031.
Substance use disorders are a major public health problem. The most common substance of abuse and/or dependence is alcohol. The World Health Organization estimates that about 140 million people throughout the world suffer from alcohol dependence. In the United States and Western Europe, 10 to 20 percent of men and 5 to 10 percent of women at some point in their lives will meet criteria for alcoholism. Most alcoholics develop alcoholism during adolescence or young adulthood. There is also broad consensus regarding alcoholism as a disease state; the American Medical Association considers alcohol a drug.
”These Notices of Allowance follow the recent launch of our Company's novel and fast drug development concept, with only few years of pre-clinical research in the field” stated Heikki Vuorikoski, founder and Acting CEO of Montisera. “The CNS related diseases are numerous, and drug addiction and alcoholism are among the two key targets of our novel platform of drugs. E.g. in the field of treating alcohol use disorders we are seeking ways to better tailor care and to make that care responsive to a patient’s changing needs. Furthermore, it will be important to combine the drug based treatment options with the existing treatment framework—such as behavioural therapies, and mutual help groups—that have been shown to have a significant impact on many people’s efforts to change their drinking”.
About Montisera Ltd
Founded in 2012, Montisera is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its own and partners’ product platforms in a broad range of disease areas. Montisera utilises a novel drug development strategy, emphasising the power of cooperation between drug development companies, biotechnology companies, academy, individual scientists and investors. This strategy follows the one first implemented on a broad scale by Chorus, an autonomous division of Eli Lilly and Company.
This news release may contain forward-looking statements that reflect Montisera’s current expectations regarding future events, including statements about whether the subject patent would be issued and adequately protect Montisera against competition, Montisera’s plan to protect the commercial potential of its product candidates, and the future status of pending patent applications. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of the Montisera’s research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of products by consumer and medical professionals. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Montisera undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.